PDCD1 and head and neck squamous cell carcinoma: Currently multiple phase II-IIII trials are recruiting HNSCC patients for combination of paclitaxel with other drugs including camrelizumab (an anti-PD-1 immune checkpoint inhibitor) and cisplatin (Phase II, NCT04826679), pembrolizumab plus carboplatin (phase IIII, NCT04489888) and bleomycin and cisplatin or carboplatin (phase II, NCT03830385).